Investing Profile

Kyle Kurpinski(3)

VCInvestor
Executive Director, Investments, Tencent Exploration Team
tenx.tcSeattle, Washington
Photo of Kyle Kurpinski, Investor at Tencent Holdings

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
University of California, Berkeley Network
251 CONNECTIONS
University of Michigan Network
87 CONNECTIONS
$100K - $30.0M
$15.0M
15
CompanyStageDateRound SizeTotal Raised
Metagenomi
Series BJan 2022$180M
$280M
Co-investors: Sebastian Bernales (Humboldt Fund), Andrew Levin (RA Capital), Victor Wang (HOF Capital), Jeremy Yap
Culture Biosciences
Series BOct 2021$80M
seedApr 2018
$100M
Co-investors: Wei Guo (UpHonest Capital), Zal Bilimoria (Refactor Capital), Dan Phillips (Sandbox Industries), Andrew Lee (Northpond Ventures), Michael Dempsey (Compound), Steven Lurie (Team Builder Ventures), Ben Davenport
Lassogen
Seed RoundOct 2020$4.5M
$9.5M
Co-investors: Peter Barrett (Playground Global), Phyllis Whiteley (Playground Global), Wes Selke (Better Ventures)
Mantra Bio
Series AJul 2020$25M
$34M
Co-investors: David Moskowitz (8VC), Francisco Gimenez (8VC)
Atomwise
Series AMar 2018$45M
$170M
Co-investors: Raj Ganguly (B Capital Group), Matt Ocko (DCVC (Data Collective)), Kiersten Stead (DCVC (Data Collective)), Xinhong Lim (Vickers Venture Partners), Saman Farid (Baidu Ventures), David E. Weekly (Mexican.vc), Farzad Nazem
Locus Biosciences
Series ANov 2017$19M
$54M
Co-investors: Austin Walne (Artis Ventures (AV)), Stuart Peterson (Artis Ventures (AV))
Karius
Series AAug 2017$59M
$330M
Co-investors: Ravi Mhatre (Lightspeed Venture Partners), Alex Morgan (Khosla Ventures), Matt Ocko (DCVC (Data Collective)), Isabelle de Cremoux (Seventure Partners)
Guardant Health
Series EMay 2017$360M
Series DJan 2016$100M
$550M
Co-investors: Pejman Nozad (Pear VC), Samir Kaul (Khosla Ventures), Matthew Rizzo (OrbiMed), Ling Wong (Highbury Group), Bobby Yazdani (Cota Capital), Sujay Jaswa (WndrCo LLC), Farzad Nazem, Chris Schaepe, David Chen, Laszlo Bock
I'm most interested in companies building deep core technologies to solve complex challenges in human health and planetary resiliency. I'm particularly drawn towards data-driven companies, and I focus heavily on those innovating at the intersection of data science and life science. I'm intrigued by the possibilities of using robotics, automation, miniaturization, and new high-throughput techniques to rapidly generate novel and actionable insights for users.
I generally do not invest companies that lack a clear and defensible core technology.
University of California, Berkeley PhD Bioengineering
University of Michigan BS Chemical Engineering